Skip to content

Developing a integrative clinical subtype and treatment model by identifying the common and differential mechanisms of cognitive dysfunction and depression.

Development of treatment model and verification of a new integrated clinical subtype based on multi-dementional analysis on the common and differential mechanisms of cognitive dysfunction and depression in cognitive dysfunction with depression.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007319
Enrollment
500
Registered
2022-05-20
Start date
2022-06-01
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Hallym University Medical Center- Chuncheon
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients over 55 years of age. 2) A person who meets the diagnosis based on the following medical diagnosis. - Diagnosis of Alzheimer's dementia and mild cognitive impairment: A patient diagnosed based on the diagnostic criteria of DSM-V and diagnostic impressions of CERAD-K (Korean Version of the Concortium to Establish a Registry of Alzheimer's Disease) evaluation. - Depression Diagnosis: Patients diagnosed with major depressive disorder, minor depressive disorder, and subsymptomatic depressive disorder using MINI-K. 3) In the normal group, except for 2). 4) A person who can voluntarily decide to participate in this clinical trial, give written consent, and perform clinical procedures including filling out questionnaires. However, if the patient is unable to make a voluntary decision due to cognitive decline, his/her legal representative may decide to participate.

Exclusion criteria

Exclusion criteria: 1) Persons with serious medical illnesses (heart failure, angina pectoris, myocardial infarction, arteriosclerosis, diabetes, inflammatory disease, malignancy, etc.) or psychiatric disease other than AD and MCI diagnosis. 2) Those diagnosed with bipolar or psychotic major depressive disorder. 3) Those with a history of seizures, brain surgery, organic brain disease or organic emotional disorder, and abnormal findings other than brain atrophy on brain MRI. 4) Those who are judged to have problems attaching EEG patches and near-infrared electrodes due to scalp deformities, inflammatory reactions, or other dermatological problems. 5) Those with a history of habitual drinking or drug abuse. 6) Patients with uncontrolled diabetes or hypertension. 7) Those who are judged to be inappropriate for this clinical trial by the investigator. 8) Patients with severe dementia (GDS score of 7 or higher or CDR score of 4 or higher).

Design outcomes

Primary

MeasureTime frame
blood biomarker;Brain function: EEG (electroencephalography), fNIRS (functional near-infrared spectroscopy);neurocognitive function tests;psychological symptomatology assessment

Secondary

MeasureTime frame
Activities of daily living

Countries

Korea, Republic of

Contacts

Public ContactJiheon Kim

Hallym University Medical Center- Chuncheon

ros205@daum.net+82-33-240-5000

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026